文献速递瓣膜病与结构性心脏病冠心病

低风险时代年轻患者球囊扩张式经导管主动脉瓣置换术的结局

Outcomes of Balloon-Expandable Transcatheter Aortic Valve Replacement in Younger Patients in the Low-Risk Era.
PubMed 文献 · JAMA Cardiol · 2025-01-01

65岁以下患者仅占5.7%,合并症负担更重,1年再入院率和全因死亡率更高;倾向性匹配后再入院率仍较高,但死亡率与老年组相似。

要点

  • 65岁以下接受BEV TAVR者仅占5.7%,二叶瓣比例更高。
  • 年轻患者合并症负担重,基线生活质量和步速更差。
  • 1年再入院率更高,匹配后死亡率与老年组相似。

核心结论

  • 在低外科风险时代,65岁以下接受BEV TAVR的患者占比较小,合并症负担高,1年死亡和再入院率高于老年对照。
  • 这些观察提示对该年龄组多数患者而言,心脏团队决策TAVR在临床上是合理的。

研究设计与样本

  • 干预为使用SAPIEN系列器械的球囊扩张式瓣膜TAVR。

主要发现

  • 1年全因死亡率65岁以下组为908[9.9%],65至80岁组为6877[8.2%](P<.001)。
  • 倾向性匹配后,年轻组再入院率仍较高(2732[28.2%] vs 2589[26.8%],P<.03),死亡率相似(905[9.9%] vs 827[10.1%],P=.55)。

关键数值与推荐

  • 指南建议所有主动脉瓣狭窄患者接受心脏团队评估,65岁以下或预期寿命超过20年者推荐外科主动脉瓣置换。
  • 若选择生物瓣,因组织瓣耐久性有限可能需要再次手术。

临床怎么用

  • 对65岁以下主动脉瓣狭窄患者,应依据指南由心脏团队综合评估合并症和预期寿命后决定TAVR或外科手术。
  • 年轻患者TAVR后需关注再入院风险,强化随访管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Guidelines advise heart team assessment for all patients with aortic stenosis, with surgical aortic valve replacement recommended for patients younger than 65 years or with a life expectancy greater than 20 years. If bioprosthetic valves are selected, repeat procedures may be needed given limited durability of tissue valves; however, younger patients with aortic stenosis may have major comorbidities that can limit life expectancy, impacting decision-making. OBJECTIVE: To characterize patients younger than 65 years who received transcatheter aortic valve replacement (TAVR) and compare their outcomes with patients aged 65 to 80 years. DESIGN, SETTING, AND PARTICIPANTS: This retrospective registry-based analysis used data on 139 695 patients from the Society for Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy (TVT) Registry, inclusive of patients 80 years and younger undergoing TAVR from August 2019 to September 2023. INTERVENTION: Balloon-expandable valve (BEV) TAVR with the SAPIEN family of devices. MAIN OUTCOMES AND MEASURES: Comorbidities (heart failure, coronary artery disease, dialysis, and others) and outcomes (death, stroke, and hospital readmission) of patients younger than 65 years compared to patients aged 65 to 80 years. RESULTS: In the years surveyed, 13 849 registry patients (5.7%) were younger than 65 years, 125 846 (52.1%) were aged 65 to 80 years, and 101 725 (42.1%) were 80 years and older. Among those younger than 65, the mean (SD) age was 59.7 (4.8) years, and 9068 of 13 849 patients (65.5%) were male. Among those aged 65 to 80 years, the mean (SD) age was 74.1 (4.2) years, and 77 817 of 125 843 patients (61.8%) were male. Those younger than 65 years were more likely to have a bicuspid aortic valve than those aged 65 to 80 years (3472/13 755 [25.2%] vs 9552/125 001 [7.6%], respectively; P < .001). They were more likely to have congestive heart failure, chronic lung disease, diabetes, immunocompromise, and end stage kidney disease receiving dialysis. Patients younger than 65 years had worse baseline quality of life (mean [SD] Kansas City Cardiomyopathy Questionnaire score, 47.7 [26.3] vs 52.9 [25.8], respectively; P < .001) and mean (SD) gait speed (5-meter walk test, 6.6 [5.8] seconds vs 7.0 [4.9] seconds, respectively; P < .001) than those aged 65 to 80 years. At 1 year, patients younger than 65 years had significantly higher readmission rates (2740 [28.2%] vs 23 178 [26.1%]; P < .001) and all-cause mortality (908 [9.9%] vs 6877 [8.2%]; P < .001) than older patients. When propensity matched, younger patients still had higher 1-year readmission rates (2732 [28.2%] vs 2589 [26.8%]; P < .03) with similar mortality to their older counterparts (905 [9.9%] vs 827 [10.1%]; P = .55). CONCLUSIONS AND RELEVANCE: Among US patients receiving BEV TAVR for severe aortic stenosis in the low-surgical risk era, those younger than 65 years represent a small subset. Patients younger than 65 years had a high burden of comorbidities and incurred higher rates of death and readmission at 1 year compared to their older counterparts. These observations suggest that heart team decision-making regarding TAVR for most patients in this age group is clinically valid.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Coylewright M, Grubb KJ, Arnold SV, et al. Outcomes of Balloon-Expandable Transcatheter Aortic Valve Replacement in Younger Patients in the Low-Risk Era. JAMA Cardiol. 2025. PMID: 39475333. doi:10.1001/jamacardio.2024.4237

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。